Genetic susceptibility to adverse drug reactions.

[1]  U. Brinkmann.  Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. , 2002, Novartis Foundation symposium.

[2]  M. Pirmohamed,et al.  TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients , 2001, Neurology.

[3]  M. Pirmohamed,et al.  Toxicogenetics in drug development. , 2001, Toxicology letters.

[4]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[5]  D. Pickar,et al.  Pharmacogenomics of psychiatric disorders. , 2001, Trends in pharmacological sciences.

[6]  D. Escande.  Pharmacogenetics of cardiac K(+) channels. , 2000, European journal of pharmacology.

[7]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[8]  J. Sullivan,et al.  Potassium channels: molecular defects, diseases, and therapeutic opportunities. , 2000, Pharmacological reviews.

[9]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[10]  S. Knowles,et al.  Idiosyncratic drug reactions: the reactive metabolite syndromes , 2000, The Lancet.

[11]  M. Pirmohamed,et al.  Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. , 2000, Pharmacogenetics.

[12]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[13]  I. Gray,et al.  Single nucleotide polymorphisms as tools in human genetics. , 2000, Human molecular genetics.

[14]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[16]  S. McGrath,et al.  Cytochrome P450 polymorphisms are associated with reduced warfarin dose. , 2000, Surgery.

[17]  R C Elston,et al.  Testing drug response in the presence of genetic information: sampling issues for clinical trials. , 2000, Pharmacogenetics.

[18]  M. Prins,et al.  Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison , 2000, The Lancet.

[19]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[20]  M. Shapira,et al.  A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. , 2000, Human molecular genetics.

[21]  T. McCarthy,et al.  Ryanodine receptor mutations in malignant hyperthermia and central core disease , 2000, Human mutation.

[22]  I. Olkin,et al.  Adverse drug reactions in hospitalized patients: A critique of a meta-analysis. , 2000, MedGenMed : Medscape general medicine.

[23]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[24]  W. Evans,et al.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia , 2000, Leukemia.

[25]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Miners,et al.  Polymorphisms in UDP Glucuronosyltransferase Genes: Functional Consequences and Clinical Relevance , 2000, Clinical chemistry and laboratory medicine.

[27]  M. Ratain,et al.  Pharmacogenetics , 2000, Clinical pharmacokinetics.

[28]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[29]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[30]  S. Aylett,et al.  Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins , 1999, Postgraduate medical journal.

[31]  Gen Tamiya,et al.  Complete sequence and gene map of a human major histocompatibility complex , 1999 .

[32]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[33]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[34]  M. Relling,et al.  High incidence of secondary brain tumours after radiotherapy and antimetabolites , 1999, The Lancet.

[35]  John A Todd,et al.  Interpretation of results from genetic studies of multifactorial diseases , 1999, The Lancet.

[36]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[37]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[38]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[39]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[40]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[41]  W. O'Fallon,et al.  Frequency of Major Complications of Aspirin, Warfarin, and Intravenous Heparin for Secondary Stroke Prevention: A Population-Based Study , 1999, Annals of Internal Medicine.

[42]  Elena S. Babaylova,et al.  Complete sequence and gene map of a human major histocompatibility complex , 1999, Nature.

[43]  J. Jespersen,et al.  Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.

[44]  P. Nowell,et al.  Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Shimizu,et al.  Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. , 1998, Pharmacogenetics.

[46]  J. Cairns,et al.  Prevention of stroke in patients with nonvalvular atrial fibrillation , 1998, Neurology.

[47]  M Pirmohamed,et al.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.

[48]  M. Pirmohamed,et al.  No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. , 1998, Pharmacogenetics.

[49]  J. Leeder.  Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs , 1998, Epilepsia.

[50]  W. Evans,et al.  Pharmacogenetics of cancer therapy: getting personal. , 1998, American journal of human genetics.

[51]  Munir Pirmohamed,et al.  Fortnightly review: Adverse drug reactions , 1998 .

[52]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[53]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[54]  J A Lewis,et al.  New active substances authorized in the United Kingdom between 1972 and 1994. , 1998, British journal of clinical pharmacology.

[55]  A. Marshall.  Getting the right drug into the right patient , 1998, Nature Biotechnology.

[56]  Brian Lipworth,et al.  Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.

[57]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[58]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[59]  David W. Bates,et al.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group , 1997 .

[60]  L. Kaminsky,et al.  Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.

[61]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[62]  M. Pirmohamed,et al.  Idiosyncratic Drug Reactions , 1996 .

[63]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[64]  M. Pirmohamed,et al.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. , 1996, Clinical pharmacokinetics.

[65]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[66]  J. Idle,et al.  Pharmacogenetics in the new patterns of healthcare delivery. , 1995, Pharmacogenetics.

[67]  M. Pirmohamed,et al.  Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. , 1995, Biochemical pharmacology.

[68]  N. Laird,et al.  Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .

[69]  M. Pirmohamed,et al.  Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. , 1995, British journal of clinical pharmacology.

[70]  M. Pirmohamed,et al.  The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. , 1995, Pharmacology & therapeutics.

[71]  D. Grant,et al.  Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. , 1994, Pharmacogenetics.

[72]  M. Pirmohamed,et al.  Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. , 1994, Archives of dermatology.

[73]  J. Gummert,et al.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.

[74]  F. Pociot,et al.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles , 1993, The Journal of experimental medicine.

[75]  M. Pirmohamed,et al.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. , 1992, British journal of clinical pharmacology.

[76]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[77]  M. Pirmohamed,et al.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. , 1991, British journal of clinical pharmacology.

[78]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[79]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[80]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[81]  A. Scott,et al.  Warfarin usage: can safety be improved? , 1989, Pharmacology & therapeutics.

[82]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[83]  E. Andermann,et al.  GENETIC PREDISPOSITION TO PHENYTOIN-INDUCED BIRTH DEFECTS , 1985, The Lancet.

[84]  R. Weinshilboum,et al.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. , 1978, Clinica chimica acta; international journal of clinical chemistry.

[85]  D. Davies,et al.  Textbook of Adverse Drug Reactions , 1992, Annals of Internal Medicine.

[86]  J. Mckenney,et al.  Drug-related hospital admissions. , 1976, American journal of hospital pharmacy.

[87]  S. R. Fine,et al.  ADVERSE DRUG REACTIONS , 2009, BMJ : British Medical Journal.

[88]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[89]  G. H. Bush,et al.  Pharmacogenetics , 1968 .